Glenmark Life Sciences Future Growth
Future criteria checks 3/6
Glenmark Life Sciences is forecast to grow earnings and revenue by 11.2% and 10.4% per annum respectively. EPS is expected to grow by 11.3% per annum. Return on equity is forecast to be 22.4% in 3 years.
Key information
11.2%
Earnings growth rate
11.3%
EPS growth rate
Pharmaceuticals earnings growth | 18.9% |
Revenue growth rate | 10.4% |
Future return on equity | 22.4% |
Analyst coverage | Low |
Last updated | 05 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 33,368 | N/A | N/A | N/A | 1 |
3/31/2026 | 30,195 | 6,571 | 3,260 | N/A | 3 |
3/31/2025 | 26,953 | 5,941 | 2,385 | N/A | 4 |
3/31/2024 | 23,913 | 5,213 | 3,056 | N/A | 4 |
12/31/2023 | 23,679 | 5,193 | N/A | N/A | N/A |
9/30/2023 | 23,359 | 5,055 | 3,224 | 4,543 | N/A |
6/30/2023 | 22,498 | 4,937 | N/A | N/A | N/A |
3/31/2023 | 21,612 | 4,670 | 1,432 | 3,134 | N/A |
12/31/2022 | 20,540 | 4,195 | N/A | N/A | N/A |
9/30/2022 | 20,357 | 4,182 | 1,991 | 3,856 | N/A |
6/30/2022 | 20,882 | 4,265 | N/A | N/A | N/A |
3/31/2022 | 21,232 | 4,187 | 4,654 | 5,976 | N/A |
12/31/2021 | 20,763 | 4,245 | N/A | N/A | N/A |
9/30/2021 | 20,541 | 4,142 | 4,443 | 5,291 | N/A |
6/30/2021 | 20,131 | 3,714 | N/A | N/A | N/A |
3/31/2021 | 18,852 | 3,516 | 3,201 | 3,881 | N/A |
3/31/2020 | 15,373 | 3,131 | 1,438 | 1,950 | N/A |
3/31/2019 | 8,864 | 1,956 | 10 | 104 | N/A |
3/31/2018 | 2 | -4 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 543322's forecast earnings growth (11.2% per year) is above the savings rate (6.7%).
Earnings vs Market: 543322's earnings (11.2% per year) are forecast to grow slower than the Indian market (18% per year).
High Growth Earnings: 543322's earnings are forecast to grow, but not significantly.
Revenue vs Market: 543322's revenue (10.4% per year) is forecast to grow faster than the Indian market (10.3% per year).
High Growth Revenue: 543322's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 543322's Return on Equity is forecast to be high in 3 years time (22.4%)